You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

bispecific antibody

Showing 1 - 25 of 5,758
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Solid Tumors Trial in Guangzhou (MR001)

Not yet recruiting
  • Advanced Solid Tumors
  • Guangzhou, Guangdong, China
    Nanfang Hospital, Southern Medical University
Nov 12, 2023

Neuroblastoma, Osteosarcoma, Other Solid Tumor Cancers Trial in New York (Humanized 3F8 Bispecific Antibody, Blood draw)

Terminated
  • Neuroblastoma
  • +2 more
  • Humanized 3F8 Bispecific Antibody
  • Blood draw
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jul 11, 2022

SCLC, Extensive Stage Trial in Shanghai (AK112, Etoposide, Carboplatin)

Recruiting
  • SCLC, Extensive Stage
  • Shanghai, Shanghai, China
    Shun Lu
Oct 12, 2022

Advanced Prostate Cancer Trial in Lyon, Villejuif, Rotterdam (JNJ-78278343, JNJ-87189401)

Not yet recruiting
  • Advanced Prostate Cancer
  • Lyon, France
  • +2 more
Oct 18, 2023

HIV-1-infection Trial in Mbeya (ART, 10E8.4/iMab, VRC07-523LS)

Not yet recruiting
  • HIV-1-infection
  • Mbeya, Tanzania
    National Institute for Medical Research-Mbeya Medical Resarch Ce
Jun 6, 2023

Malignant Tumor Trial in Shanghai (PM8002)

Recruiting
  • Malignant Neoplasm
  • Shanghai, Shanghai, China
    Shanghai Orient Hospital
Jun 25, 2023

Multiple Myeloma Trial (Teclistamab, Tocilizumab)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Jul 24, 2023

Prostate Cancer Recurrent Trial in Tuebingen (CC-1 Infusion)

Recruiting
  • Prostate Cancer Recurrent
  • CC-1 Infusion
  • Tuebingen, Germany
    University Hospital Tuebingen
Jan 10, 2023

SCLC,Extensive Stage Trial in Changchun (AK104 IV infusion;Chiauranib oral)

Not yet recruiting
  • SCLC,Extensive Stage
  • AK104 IV infusion；Chiauranib oral
  • Changchun, Jilin, China
    Jilin Province Cancer Hospital
Aug 16, 2022

Solid Tumor Trial in China (SI-B003)

Recruiting
  • Solid Tumor
  • Beijing, Beijing, China
  • +7 more
Jan 11, 2023

Advanced Solid Tumor, NSCLC, Small Cell Lung Cancer Trial (IMM2520)

Not yet recruiting
  • Advanced Solid Tumor
  • +5 more
  • (no location specified)
Mar 20, 2023

Peripheral T-cell Lymphoma Trial in Beijing (AK104)

Terminated
  • Peripheral T-cell Lymphoma
  • AK104
  • Beijing, Beiing, China
    Beijing Cancer Hospital
Oct 17, 2022

Hepatocellular Carcinoma Trial in Beijing (AK104, Lenvatinib)

Recruiting
  • Hepatocellular Carcinoma
  • Beijing, Beijing, China
    Chinese PLA General Hospital
Oct 17, 2022

Hepatocellular Carcinoma Trial in Guangzhou (Cadonilimab, transjugular intrahepatic portosystemic shunt (TIPS))

Not yet recruiting
  • Hepatocellular Carcinoma
  • Cadonilimab
  • transjugular intrahepatic portosystemic shunt (TIPS)
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
May 30, 2023

Hepatocellular Carcinoma Trial in Hangzhou (AK104 lenvatinib, AK104)

Active, not recruiting
  • Hepatocellular Carcinoma
  • AK104 lenvatinib
  • AK104
  • Hangzhou, Zhejiang, China
    The first affilited hospital zhejiang university school of medci
Oct 17, 2022

Primary Sjogren's Syndrome Trial in Palo Alto (tibulizumab (LY3090106))

Withdrawn
  • Primary Sjogren's Syndrome
  • tibulizumab (LY3090106)
  • Palo Alto, California
    Stanford University
Jan 12, 2022

Cadonilimab in Recurrent or Metastatic Cervical Cancer

Not yet recruiting
  • Recurrent or Metastatic Cervical Cancer
  • (no location specified)
Nov 23, 2023

Solid Tumor, Adult Trial in Guangzhou (AK112)

Active, not recruiting
  • Solid Tumor, Adult
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 8, 2022

Myeloproliferative Disorders, Essential Thrombocythemia, Tumors Trial (JNJ-88549968)

Not yet recruiting
  • Myeloproliferative Disorders
  • +3 more
  • (no location specified)
Nov 21, 2023

B-Cell Lymphoma Trial in Heidelberg, Melbourne, Nedlands (TG-1801, Ublituximab)

Active, not recruiting
  • B-Cell Lymphoma
  • Heidelberg, Victoria, Australia
  • +2 more
Jan 20, 2023

Pediatric Cancer, Hodgkin Disease, CD30-Positive DLBCL Trial in Milwaukee (anti-CD30 Bispecific Antibody-armed

Not yet recruiting
  • Pediatric Cancer
  • +11 more
  • anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
  • Milwaukee, Wisconsin
    Children's Wisconsin
Sep 14, 2022

Advanced Solid Tumor Trial (ES014)

Withdrawn
  • Advanced Solid Tumor
  • (no location specified)
Jan 30, 2023

Biliary Tract Cancer, Candonilimab, Claudin 18.2 Trial in Shanghai (cardonilizumab, LM-302)

Recruiting
  • Biliary Tract Cancer
  • +2 more
  • Shanghai, China
    Zhongshan hospital, Fudan University
Aug 12, 2023

Colorectal Cancer Trial (Administration of CC-3)

Not yet recruiting
  • Colorectal Cancer
  • Administration of CC-3
  • (no location specified)
Aug 11, 2023

Advanced Malignant Tumors(Stage IA-IB) Trial in Beijing (AK129 IV infusion)

Not yet recruiting
  • Advanced Malignant Tumors(Stage IA-IB)
  • AK129 IV infusion
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Science
Jan 17, 2023